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Abstract 
 
Squamous cell carcinoma and adenocarcinoma are the main types of 
pulmonary malignant epithelial tumours and are the main cause of death from cancer. 
Considering the increasing incidence of these pathologies in advanced stages prone to 
targeted therapy, unravelling the molecular mechanisms underlying their development 
and characterising the differences between the two histological types becomes essential. 
microRNAs have been recently identified as important regulators of gene expression at 
the post-transcriptional level, playing a key role in tumourigenesis. miR-126 and miR-
126* are two of those regulators and several studies confirm their importance in cancer. 
However, a detailed characterization of these microRNAs in pulmonary carcinoma is 
lacking. 
In this study, we performed laser microdissection of squamous cell carcinoma 
and adenocarcinoma samples, as well as of matched pulmonary parenchyma and lymph 
node metastasis from surgical specimens to evaluate the expression of miR-126 and 
miR-126* by real-time PCR.  
miR-126 and miR-126* presented lower expression in primary pulmonary 
carcinomas and lymph node metastasis when matched with pulmonary parenchyma. 
Primary carcinomas and lymph node metastasis presented similar expression, as well as 
tumours of patients with and without lymph node metastasis. Adenocarcinomas from 
female patients presented lower levels of miR-126 and miR-126* than the cases of male 
patients. In male gender, squamous cell carcinomas presented lower levels than 
adenocarcinomas. In addition, pulmonary parenchyma from male patients with 
squamous cell carcinoma and from female patients with adenocarcinoma presented 
higher expression than the pulmonary parenchyma of male patients with 
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adenocarcinoma. These results support a role for these microRNAs in pulmonary 
adenocarcinoma and squamous cell carcinoma carcinogenesis and progression from 
early stages and suggest that they could be used as biomarkers to distinguish between 
the histological types and for an early detection of adenocarcinomas.  
An attempt of characterising the methylation pattern of miR-126/miR-126* 
host gene promoter by MS-PCR was made. However, adequate primer design for this 
particular region presented some constraints. Other alternatives should be therefore 
considered for this type of analysis.    
 
Key words: squamous cell carcinoma, adenocarcinoma, miR-126, miR-126* 
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Resumo 
 
O carcinoma epidermóide e o adenocarcinoma são os principais tipos de 
tumores epiteliais malignos e são a principal causa de morte por cancro. Tendo em 
conta a crescente incidência destas patologias em estádios avançados propensos a 
terapia dirigida, torna-se essencial perceber os mecanismos moleculares subjacentes ao 
seu desenvolvimento e caracterizar as diferenças entre os dois tipos histológicos. Os 
microRNAs foram recentemente identificados como importantes reguladores da 
expressão génica ao nível pós-transcricional, desempenhando um papel chave na 
tumorigénese. O miR-126 e o miR-126* são dois destes regulares e vários estudos 
confirmam a sua importância no cancro. Contudo, não existe uma caracterização 
detalhada destes microRNAs nos carcinomas pulmonares. 
Neste estudo realizou-se microdissecção a laser de amostras de peças cirúrgicas 
de carcinoma epidermóide e adenocarcinoma, assim como do parênquima pulmonar e 
metástases dos gânglios linfáticos correspondentes, e avaliou-se a expressão do miR-
126 e do miR-126* por PCR em tempo real.  
O miR-126 e o miR-126* apresentaram menor expressão nos carcinomas 
pulmonares primários e nas metástases dos gânglios linfáticos do que no parênquima 
pulmonar correspondente. Os carcinomas primários e as metástases dos gânglios 
linfáticos apresentaram expressão semelhante, assim como os tumores de doentes com e 
sem metástases dos gânglios linfáticos. Os adenocarcinomas de doentes do género 
feminino apresentaram menores níveis de miR-126 e miR-126* do que os dos doentes 
do género masculino. No género masculino, os carcinomas epidermóides apresentaram 
menores níves do que os adenocarcinomas. Além disso, o parênquima pulmonar das 
peças cirúrgicas de doentes do género masculino com carcinoma epidermóide e de 
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doentes do género feminino com adenocarcinoma apresentou maior expressão do que os 
de doentes do género masculino com adenocarcinoma. Estes resultados apontam para 
um papel destes microRNAs na carcinogénese de adenocarcinoma e carcinoma 
epidermóide pulmonares e progressão em fases iniciais e sugerem que estes possam ser 
utilizados como biomarcadores para distinguir os dois tipos histológicos e para uma 
detecção precoce dos adenocarcinomas. 
Tentou-se caracterizar o padrão de metilação do promotor do gene hospedeiro 
dos miR-126/miR-126* por MS-PCR. Contudo, o desenho de primers adequados para 
esta região em particular apresentou algumas restrições. Assim, outras alternativas 
devem ser consideradas para este tipo de análise. 
 
Palavras-chave: carcinoma epidermóide, adenocarcinoma, miR-126, miR-126* 
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CANCER 
 
Cancer is one of the leading causes of death worldwide. Its incidence has been 
increasing and it is now the cause of more than 10% of deaths. The number of cases of 
cancer is predicted to increase even further and it is estimated that 12 million people 
will die from it in 2030 [1]. Considering this high incidence and mortality and the 
problems still prevalent regarding therapy and relapse, cancer has been a major focus in 
health research. However, this is a complex and highly ramified disease. Hence, many 
of the underlying principles remain to be elucidated and their connections established.  
 
Cancer hallmarks 
 
The normal cell pattern of division and death is tightly controlled in order to 
ensure that cell proliferation only takes place when necessary. Cancer arises when this 
regulation fails and uncontrolled proliferation and inappropriate survival of damaged 
cells occur, which results in tumour formation.  
There are several pathways involved in the regulation of these processes and 
consequently several components whose dysregulation may promote tumourigenesis.  
Notwithstanding, it is widely accepted that the wide range of modifications underlying 
cancer development can be grouped in eight main categories, the hallmarks of cancer, 
proposed by Hanahan and Weinberg. Although their acquisition might differ both 
mechanistically and chronologically, all cancers are believed to share these traits: self-
sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion to 
programmed cell death, limitless replicative potential, sustained angiogenesis, tissue 
invasion and metastasis,  energy metabolism reprogramming and evasion to immune 
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destruction. The disruption of the defences against each of these characteristics has a 
partial contribution in cancer development. It has been proposed that the acquisition of 
cancer hallmarks is made possible by two enabling characteristics: genome instability 
and mutation and tumour-promoting inflammation [2]. 
As pointed out by Hanahan and Weinberg, angiogenesis is a central step in 
carcinogenesis. It consists on the development of new blood vessels from pre-existing 
vessels and is fundamental for the tumour to grow, since it allows the necessary supply 
of nutrients and oxygen to the tumoural cells. The process of angiogenesis is regulated 
by the balance between pro- and anti-angiogenic factors. When this balance is altered 
towards angiogenesis, an “angiogenic switch” is said to occur. This event leads a 
dormant avascularized hyperplasia to become a vascularized tumour and eventually to 
metastasize [3]. The angiogenic switch can be triggered by several signals, such as 
metabolic stress, mechanical stress and immune response, as well as genetic mutations 
[4].  
Metastases, a central feature of many tumours, originate from a multistage 
process that leads to the spread of malignant cells from primary tumours to distant sites. 
Tumour cells become metastatic by a series of events, in which epithelial-mesenchimal 
transition (EMT) plays a central role. In this process, epithelial cells acquire genomic 
and functional characteristics resembling those of mesenchymal cells. After EMT, these 
cells travel through the vasculature and proliferate in other tissues, from microscopic 
growths (micrometastases) to macroscopic secondary tumours (macrometastases), either 
in lymph nodes and organs as the lungs, liver, bones and brain [5].  
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Signalling pathways 
 
Cancer arises due to the disruption of the normal functioning of several 
signalling pathways (Fig. 1). These pathways consist of complex webs of components, 
from membrane signal receptors that activate membrane or cytoplasmic intermediary 
proteins, promoting signal propagation, to downstream components that translocate to 
the nucleus and alter gene expression. Signalling pathways are involved in every cell 
process, from cell cycle control to DNA damage repair and apoptosis. Their alteration 
can therefore lead to one or more of the cancer hallmarks and promote tumour 
formation [2].  
  
Figure 1. Signalling pathways involved in cancer. Cell functioning and fate are controlled by a complex 
web of signalling pathways that respond to several stimuli through membrane receptors. These receptors 
allow signal transduction to intracellular components and eventually nuclear effects at the gene expression 
regulation level. Different stimuli activate different pathways, thus leading to specific effects in cancer [2].  
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Methylation 
 
Methylation of DNA is an epigenetic process, that is, a process that changes 
DNA without altering the nucleotide sequence. It consists on the transfer of a methyl 
group to a cytosine ring, a reaction catalyzed by DNA methyltransferases (DNMTs) that 
leads to gene silencing. In mammals, it occurs at cytosines located 5’ of a guanosine 
(cytosine-phosphate-guanine (CpG) dinucleotides). Regions with high CpG content are 
known as CpG islands and locate mainly in the proximal promoter regions of genes. 
Methylation is known to play a central role on embryonic development, genomic 
imprinting and inactivation of genes on the X chromosome [6].  
As a function in normal processes, methylation also plays an important role in 
some pathological conditions, such as cancer. Tumoural cells usually present abnormal 
patterns of DNA methylation, with hypermethylated CpG islands in gene promoters and 
hypomethylation of gene coding-sequences. Promoter hypermethylation has been 
extensively related to tumourigenic features. For instance, methylation of TIMP 
metallopeptidase inhibitor 3 (TIMP-3), which encodes a protease inhibitor, leads to 
tissue invasion in cancer [7]. Also, hypermethylation patterns can be used as diagnostic 
markers. Herman and colleagues have shown that different types of tumours present 
specific hypermethylation patterns, which can be useful for diagnosis [8]. A central 
feature of this kind of alteration is that they are reversible, therefore being potential 
therapeutic targets. 
 
Oncogenes and tumour suppressor genes 
 
Genes involved in cancer can be divided into two main categories: oncogenes, 
cancer-promoting genes, and tumour suppressor genes, whose activity contributes to 
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prevention of carcinogenesis. In normal conditions, these genes are usually switched off 
and on, respectively. However, the activation of oncogenes and the inactivation of 
tumour suppressor genes can lead to drastic changes in the signalling pathways and 
originate conditions that promote the alterations underlying the hallmarks of cancer, 
thus leading to tumour formation [2]. 
Although the focus on these genes used to concern mainly protein-coding ones, 
it has been recently discovered that some non-coding RNA genes can also act as 
oncogenes or tumour suppressor genes, playing an important role in cancer. These 
genes codify small molecules of RNA, called microRNAs, which present an extensive 
function in gene expression regulation and whose significance in cancer has been 
acknowledged as more studies in this area are carried out [9]. 
 
MICRORNAS 
 
microRNAs constitute a family of approximately 22-nucleotide (nt) small 
RNAs with a crucial role on gene expression regulation at the post-transcriptional level, 
by complementary binding to target messenger RNA (mRNA) molecules [10]. 
microRNAs were first identified in Caenorhabditis elegans during a genetic 
screening on which it was found that mutations in gene lin-4 (abnormal cell lineage 4) 
lead to disruption of temporal regulation in larval development [11]. The 
characterization of this gene as a microRNA gene was made later by Ambros and 
colleagues, who described that the transcript contained sequences complementary to 
regions of the 3’ untranslated region (UTR) of other gene mRNA. It was then suggested 
that lin-4 could be a member of a new class of regulatory genes that would act by 
originating small RNA products, antisense to their targets [12]. This was followed by 
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the identification of many other microRNAs in C. elegans. Posterior studies identified 
microRNAs also in plants and other animals, including humans, and established their 
importance in several processes such as cell differentiation, proliferation, apoptosis, 
metabolism and morphogenesis [13] [14]. 
 
microRNA genomics and biogenesis 
 
The human genome is predicted to contain hundreds of microRNA genes. 
Several are located in intergenic regions but the majority is placed within transcription 
units, mainly in introns of protein-coding genes [15]. Many microRNAs present the 
same orientation as the host gene, which enables coupling of microRNA expression 
with its host gene and so microRNA and mRNA present similar expression profiles. 
This could be a way of acquiring a more efficient expression but could also reflect a 
genetic interaction between the microRNA and its host [16]. Actually, it has been 
shown that microRNAs residing within protein-coding genes are processed from 
capped, polyadenylated transcripts, which are characteristics of messenger RNA, and 
that the transcript can then originate either microRNA or mRNA, depending on its 
further processing [17]. Furthermore, a microRNA has been found that localizes within 
an intron of a protein coding gene and which is expressed in stress conditions, targeting 
the mRNA resulting from its host gene [18].  
microRNAs are transcribed as large RNA precursors and then undergo a 
complex multistep processing (Fig.2) that leads to a double-stranded RNA of 
approximately  22 nt with a 2 nt 3’ overhang in both strands, the 
microRNA:microRNA* duplex. Afterwards, the two strands undergo different 
processes: one of them gets associated to a multiprotein complex named RNA-induced-
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silencing complex (RISC) and will be responsible for the post-transcriptional regulation, 
whereas the microRNA* strand (also called passenger strand) is degraded [19].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The process underlying microRNA:microRNA* dissociation has not been fully 
elucidated yet. Several reports have identified different helicases intervening in this 
event [20] [21], but there are also evidence that these kind of proteins might not be 
required [22]. The fact that only one strand of the duplex associates with RISC raises a 
question about the mechanism by which the distinction between them is made. Two 
Figure 2. microRNA biogenesis. In the nucleus, microRNAs are transcribed by RNA Pol II or III in a long 
precursor presenting a hairpin stem, a terminal loop and a 2-nt overhang at both 3’ and 5’ ends. This precursor 
molecule, called pri-microRNA, is cleaved twice, first in the nucleus by the Drosha/DGCR8 complex, 
originating pre-microRNA and, after translocation to the cytoplasm through exportin-5-Ran-GTP, by the 
Dicer/TRBP complex. This second cleavage yields a microRNA duplex: one strand is incorporated into RISC 
and originates the mature microRNA and the other is usually degraded. RNA Pol – RNA polymerase; pri-
microRNA – primary microRNA; DGCR8 – DiGeorge syndrome critical region gene 8; pre-microRNA – 
precursor microRNA; Ran – RAS-related nuclear protein; GTP – guanosine triphosphate; TRBP – Tar RNA 
binding protein; Ago2 – argonaute 2  (adapted from [19]).  
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studies revealed that the different fates of each strand are determined by the 
thermodynamic stability of the base pairs at the 5’ ends: the strand with the less stable 
5’ end is incorporated in RISC and the other strand is degraded [23]. This model implies 
that when the stability of both 5’ ends is similar, such distinction cannot be made; in this 
case, both strands would be equally likely to be incorporated. It has been proposed that 
the shared activity of both strands regulates the activity of targets with similar 
complementarity to either of them [24]. However, the incorporation of one of the 
strands instead of the other could also be tissue- and developmental-specific [25]. One 
way this could be regulated is by editing of one of the strands. For instance, pri-
microRNA editing, in which adenosine are converted to inosine by deamination, have 
shown to occur and alter the thermodynamic properties of the duplex, potentially 
leading to higher levels of the microRNA* strand [26].  
 
microRNA activity 
 
microRNA post-transcriptional control of gene expression occurs through two 
main processes: endonucleolytic mRNA cleavage, less common in animals, and 
translation prevention without mRNA degradation. This control relies on microRNA 
complementarity to the target mRNA molecules and the properties of the microRNA-
mRNA binding determine the mechanism by which the regulation takes place. When 
microRNAs present perfect or high complementarity to the protein-coding sequence of 
a mRNA, the binding leads to mRNA cleavage by RISC. However, more commonly the 
microRNA molecule only presents partial complementarity to the target molecule, 
usually to regions in the mRNA 3’ UTR. In this case, the binding of RISC microRNA to 
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its target usually only prevents mRNA translation but not its degradation. Thus the 
levels of mRNA are maintained and only the protein levels decrease [27].  
 
mRNA targeting 
 
In an attempt to ascertain the principles guiding microRNA-mRNA target 
binding, several studies have been performed that allowed the identification of some 
general rules of this recognition.  
microRNAs usually bind to the 3’ UTR of the target mRNA, although some 
also bind to the coding sequence [27]. According to Cohen and colleagues, microRNA 
target sites can be divided in two broad categories: 5’ dominant sites and 3’ 
compensatory sites, generally corresponding to the two main types of gene expression 
regulation by microRNAs (mRNA degradation and translation inhibition, respectively). 
Targets with 5’ dominant sites base-pair well to the 5’ end of the microRNA, mainly to 
the seed (nucleotides 2-7) and targets with 3’ compensatory sites present weak 5’ base-
pairing and highly depend on compensatory pairing to the 3’ end of the microRNA [28]. 
Another central characteristic in microRNA-mRNA binding is the target site 
multiplicity: the presence of several binding sites for a microRNA in a mRNA molecule 
has been shown to increase the regulation efficacy [29].  
Even though these characteristics have long been considered central to the 
microRNA-mRNA recognition, accumulating evidence points to several exceptions and 
reveals the lack of knowledge still prevailing on this issue. For example, it has been 
shown that the “seed rule” (importance of the seed region in microRNA-mRNA 
binding) is not as general as previously thought [30] and that high complementarity 
between the seed region of a microRNA and mRNA may not be sufficient to promote 
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their interaction [31]. In addition, in spite of the greater significance of the 3’ UTR 
comparatively to the 5’ UTR that is found in the microRNAs targets described so far, 
artificial constructs with target sites in the 5’ UTR presented equally efficient 
transcription as the one seen in the equivalent microRNA-3’ UTR interaction [32].  
Although much is still to uncover about this subject, it is clear that microRNAs 
have the capacity to regulate the expression of many of the genes in an organism. Due 
to the characteristics of target recognition, one microRNA can affect the expression of 
hundreds of genes [33] [34] and it is estimated that 30% of the protein coding genes are 
under microRNA regulation [34]. In spite of the difficulties concerning microRNA-
target interaction elucidation and the imprecision of the general principles so far 
recognized, the establishment of some general rules widely observed, even if not 
applicable to a subset of microRNAs, provided a way for determining potential 
microRNA targets by bioinformatic predictive approaches. Several bioinformatic tools 
have been developed that make these predictions according to different criteria, such as 
seed pair stringency, site number and overall pairing stability, among others [35]. These 
tools have been deeply valuable in the prediction of thousands of potential microRNA 
targets, some of which were later validated [36] [37]. Nonetheless, one should keep in 
mind that owing to the unclear aspects of this subject, and consequently the flaws in the 
models used to make these predictions, it is likely that many microRNA targets are not 
predicted by such approaches, therefore remaining unknown. 
 
A in canmicroRNA in cancer 
 
Since high complementarity between a microRNA and its target is not a 
requirement for microRNA activity, microRNAs may present hundreds of targets and  
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are predicted to regulate a large part of the human genome [38]. Therefore, it is not 
surprising that these regulators are involved in countless processes [13] [14] and that all 
the main cell signalling pathways are microRNA-regulated, namely those that are 
involved in cancer (Table I) [39]. Accordingly, microRNA impaired expression has 
been implicated in tumourigenesis and this expression correlates with several cancers. 
Some microRNA genes can function either as oncogenes or tumour suppressor genes 
and the microRNAs are therefore called oncomirs [9]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target microRNAs Biological processes 
Transforming growth factor-β 
ACVR2A miR-15 
miR-16 
Early embryogenesis 
Smad3, Smad4 and Smald5 miR-23b Liver stem cell differentiation 
Hedgehog 
Smoothened miR-324-5p 
miR-125b 
miR-326 
Neural stem cell proliferation 
and medulloblastoma 
GLI1 miR-324-5p Neural stem cell proliferation 
and medulloblastoma 
Receptor tyrosine kinase and mitogen-activated protein kinase 
NRAS, KRAS let-7 Cancer cell differentiation 
Sprouty1 miR-21 Cardiac fibrosis 
Receptor tyrosine kinase and AKT 
PI3KR2 miR-126 Angiogenesis 
PTEN miR-21 Hepatocellular cancer 
miR-26a Glioma 
miR-216a 
miR-217 
Glomerular mesangial cell 
survival and hypertrophy 
Hippo   
LATS miR-372/373 Testicular germ cell tumour 
p53   
TP53 miR-125b Apoptosis in brain 
TP63 miR-203 Keratinocyte differentiation 
Table I. microRNA involvement in signalling pathways (adapted from [39]). 
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The first evidence that microRNAs could be involved in cancer came from 
studies on chronic lymphocytic leukaemia in which it was found that two microRNA 
genes, miR-15 and miR-16, are located in a region deleted in a high number of cases of 
this cancer [40]. Further studies confirmed that these regulators are often dysregulated 
in cancer: a high number of microRNAs are located at fragile sites, minimal regions of 
loss of heterozygosity, minimal regions of amplification and breakpoint regions, regions 
that are usually involved in cancer [41]; Dicer is downregulated in lung cancer and its 
expression correlates with shortened post-operative survival [42]; tumours tend to 
express lower levels of microRNAs than normal tissues (though some microRNAs are 
up-regulated) [9].  
The alterations in microRNA expression could be potentially useful in cancer 
diagnosis since it has been shown that specific microRNA profiles constitute signatures 
that distinguish tumoural from normal tissues and allow the identification of different 
kinds of cancer [43]. microRNAs are also promising tools for cancer prognosis, as first 
evidenced by the work of Takahashi and colleagues describing an association between 
reduced expression of the microRNA lethal-7 (let-7) and shortened post-operative 
survival in patients with lung cancer [44]. Moreover, it has been suggested that 
microRNA signature of a tumour reflects its developmental history, since distinct 
patterns of microRNA expression are present within a single developmental lineage 
[45]. 
The importance of microRNA expression in diagnosis and prognosis and its 
impact on cancer has been further acknowledged with the discovery that this expression 
can vary not only from normal tissue to primary tumours but also from metastatic to 
non-metastatic primary tumours and from primary tumours to metastasis. Several 
studies have shown that some microRNAs are highly expressed in primary tumours that 
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metastasize whereas others present inversely correlated expression with metastatic 
behaviour and constitute therefore a way to evaluate the aggressiveness of a tumour 
[46]. Other microRNAs have been found to be altered in the cells from a primary 
tumour that acquire metastatic characteristics, comparatively to the other cells in that 
tumour [47] [48] [49]. One of the first studies identifying this correlation between 
metastatic potential and microRNA profile approached breast cancer metastasis in lung 
and bone. Massagué and colleagues proposed that the loss of specific microRNAs 
would provide a selective advantage for cells destined for metastatic colonization due to 
altered regulation of metastasis genes, such as those involved in EMT and cell adhesion 
[50]. This and other reports identified specific microRNAs metastasis signatures and 
thus revealed the potential of microRNA as prognostic markers for the risk of future 
metastasis. The role of some microRNAs not only in primary tumours development but 
also in metastatic progression relies on their capability to regulate several mRNA 
targets. According to the group of targets of a microRNA, this regulator can act as 
oncogene and/or as metastasis-promoter (or conversely as tumour-suppressor and/or 
metastasis-inhibitor).  
An important consequence arising from microRNA involvement in cancer is 
their potential as targets for cancer therapy. Oncogenic microRNAs could be targeted by 
using complementary molecules, the anti-microRNA oligonucleotides, the antagomirs, 
that have been shown to effectively inhibit microRNA activity when injected into mice 
and thus constitute promising therapeutic agents. On the other hand, microRNAs that 
function as tumour suppressors could be overexpressed through transient expression 
systems that would administer large quantities of the microRNA. However, these 
procedures are still under study and their effective clinical potential has not been 
determined yet [9].  
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Figure 3. Methylation of microRNA genes specific of metastatic primary tumours. Some 
microRNAs genes, such as miR-148a and miR-34b/c, present metastasis-specific methylation, being 
normally expressed in primary tumours that do not metastasize. Consequently, the methylation of these 
genes highly influences the capacity of a tumour to develop metastasis. DNA demethylationg drugs 
revert this methylation pattern. White circle, unmethylated CpG; black circle, methylated CpG. [56] 
 
microRNA dysregulation 
 
The processes that lead to microRNA dysregulation, namely in cancer, have 
been extensively studied and found to be caused by several factors: transcriptional 
dysregulation, which can occur through the activity of several proteins, such as p53 and 
c-Myc; germ-line or somatic mutations of microRNA genes; DNA copy number 
abnormalities, which alter DNA dosage; defects at the biogenesis level owed to 
dysfunctional or dysregulated proteins involved in this process, such as Dicer; and 
epigenetic alterations [51]. One of the major epigenetic alterations is methylation, 
whose association with cancer has already been established. Several microRNAs have 
been found to be downregulated due to hypermethylation in some cancers. Plus, 
methylation of some of these has been associated to metastatic potential, since 
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methylation signature was predictive of lymph node metastasis (Fig. 3) [52]. This could  
have significant consequences at the clinical level, since the expression of some 
microRNAs has been shown to return to normal levels after treatment with 
demethylating drugs. This was first shown for miR-127, which is downregulated in 
prostate, bladder and colon tumours. When treating tumour cell line with 5-aza-2’-
deoxycytidine (5-Aza-dC), a DNA demethylating agent, its expression was partially 
restored and led to reduced levels of one of its targets, B-cell lymphoma 6 (BCL6) [53].    
 
MICRORNAS IN PULMONARY CARCINOMA 
 
Pulmonary carcinoma, commonly called lung cancer, is the leading cause of 
death from cancer worldwide and has one of the highest incidences, representing 17.8% 
of cancer deaths and 12.6% of all new cases cancers. This disease presents 5-year 
survival rates of approximately 10% and is usually diagnosed at an advanced stage [54]. 
Hence, it becomes important to improve the knowledge about this cancer and optimize 
diagnosis and prognosis techniques. 
Tobacco smoking represents the main cause of pulmonary carcinoma, as 
supported by both epidemiological and molecular studies. This is due to the presence of 
several carcinogens and inflammation-related agents. However, only 10%-15% of 
smokers develop pulmonary carcinoma. Other factors contribute for this disease, which 
is usually the result of a combination of genetic and other environmental factors, such as 
air pollution [55].  
Pulmonary carcinoma was usually divided into two main groups, small cell 
lung cancer (SCLC), with a more rapid growth and early development of metastasis, 
and non-small cell lung cancer (NSCLC), which included squamous cell carcinoma, 
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adenocarcinoma and large cell carcinoma. This distinction was made mainly for 
treatment purposes, since SCLC was usually treated with chemotherapy and 
radiotherapy, whereas NSCLC patients were usually subject to surgery based on 
staging. However, this division is nowadays considered inadequate because NSCLC 
showed to be a very heterogeneous group and SCLC is today prone to surgery when in 
limited stage [54]. Therefore, there is the need of a personalized characterization of the 
tumours of each group. This becomes of the most importance to choose the adequate 
treatment, especially considering the opportunities that are now offered by targeted 
therapies. 
The classification of the histological type of pulmonary carcinoma is made 
according to their microscopic features, using haematoxylin and eosin (H&E)-stained 
sections. These compounds stain the nucleus and the cytoplasm, respectively, thus 
allowing a better identification of characteristic features of each type of carcinoma [55].  
 
Pulmonary squamous cell carcinoma and adenocarcinoma 
 
Squamous cell carcinoma and adenocarcinoma are the most prevalent types of 
lung carcinoma (25% and 40%, respectively) [54]. 
Squamous cell carcinoma is a malignant epithelial tumour that is characterized 
by the presence of cellular keratinization and/or intercellular bridges (Fig. 4A). It arises 
mainly from bronchial epithelium after metaplasia, is highly associated with tobacco 
smoking (90% of the cases) and is more predominant in males; it may also show 
isolated and bizarre-shaped cells forming groups that are separated by fibrous stroma in 
less differentiated cases. Cells at the periphery of the nests are usually smaller, whereas 
23 
 
those found centrally are larger, with more cytoplasm, and present more keratinization 
and intercellular bridges [54] [55].  
Adenocarcinoma is a malignant epithelial tumour with glandular, acinar or 
pappilary differentiation with or without epithelial mucin (Fig. 4B) [56]. It is the most 
common histological subtype of pulmonary carcinoma nowadays and also develops 
mainly in smokers. However, this is the histological type with a more strong correlation 
with non-smokers, particularly women. Adenocarcinoma is characterized by large cells, 
which may be single or arranged in clusters, originating the referred patterns. Cells are 
cyanophilic and more translucent in comparison with squamous cell carcinoma and 
present single and eccentric nuclei and prominent nucleoli. The characteristics of 
chromatin correlate to the degree of differentiation of the tumour: it is granular and 
evenly dispersed in highly-differentiated tumours, whereas it presents irregular 
distribution or hyperchromatin in less differentiated adenocarcinomas [54] [55].  
 
 
 
 
Pulmonary carcinoma staging is done according to the TNM system [57], 
which describes general characteristics of the primary tumour (T), such as size and 
Figure 4. (A) Adenocarcinoma  and (B) squamous cell carcinoma of the lung. H&E staining, 200x. 
A B 
24 
 
organ invasion, and the status of regional lymph nodes (N) and distant metastases (M). 
Based on this system, the stage of the tumour can then be classified into four major 
subgroups (I-IV). This staging system reflects the 5-year survival rates of lung cancer 
patients and is thus useful for prognosis and to determine the best treatment option for 
each patient.  
 
Methylation in pulmonary carcinoma 
 
Methylation is an important event in pulmonary carcinoma. Several genes have 
been described as being hypermethylated and are associated to different functions that 
are impaired in this pathology, such as DNA repair (O-6-methylguanine-DNA 
methyltransferase - MGMT) and cell cycle control (retinoblastoma - RB). In fact, 
methylation has been shown to be an early event in the development of this type of 
cancer and to be related to the progression and aggressiveness of lung cancer [58]. This 
is the case of p16, a cell cycle control gene, which has been shown to become 
hypermethylated in rats by exposure to radiation, heavy metals and tobacco carcinogens 
[59]. The silencing of this gene increased from cell hyperplasia to more advanced stages 
of the disease, in rats and in human tissue samples [60]. Minna and colleagues showed 
that this silencing mechanism presents a very high percentage in lung tumours and is 
likely to be the main process of gene silencing in this type of cancer [61]. Besides, p16 
promoter methylation presents differences between squamous cell carcinoma and 
adenocarcinoma and is associated with smoking habits and short post-surgery survival 
[62]. Other genes have also been described to be more frequently methylated in one of 
the histological types of than in the other [63] [64]. 
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The value of therapeutic strategies targeting this silencing mechanism has 
already been approached in several studies. For instance, Baylin and colleagues have 
shown that disruption of DNMT1 in mice leads to a 50% decrease in tobacco 
carcinogen-induced lung cancer. In DNMT1 wild-type mice, treatment with the 
demethylating agent 5-aza-dC decreases tumour incidence by 30% [65]. These studies 
highlight the importance of clarifying the methylation mechanisms in pulmonary 
carcinoma, as well as the methylation patterns and their molecular consequences. 
 
microRNA expression 
 
microRNA expression has proved to be very useful in pulmonary carcinoma  
studies, for both diagnosis and prognosis. Furthermore, several molecular aspects of 
microRNA activity in pulmonary carcinoma have already been elucidated.  
One of the first microRNAs to be identified, let-7, was found to be 
downregulated in lung cancer and related to shortened post-operative survival [44]. 
Besides, this was the first oncomir that was shown to regulate the expression of an 
oncogene, RAS. Slack and colleagues reported that this gene contains let-7 
complementary sites in its 3’ UTR and that low expression of let-7 correlated to higher 
levels of RAS [66]. This microRNA was later shown to reduce tumour growth in mouse 
models of lung cancer, confirming its relevance in this pathology and providing 
evidence that it could be a therapeutic target [67].  
Some microRNA profiles have been identified that allow discriminating 
tumour from normal tissues in lung and different histological types, as well as predict 
survival [68]. For instance, miR-205 has been used to distinguish squamous from non-
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squamous lung carcinomas with a 96% sensitivity and a 90% specificity [69], clearly 
showing the potential of microRNAs in diagnosis.  
Several microRNAs present altered expression in pulmonary carcinoma and a 
link has already been established between these alterations and most of the processes 
involved in tumourigenesis and metastasis formation: regulation of growth factor 
receptors (e.g. miR-128b and let-7), regulation of proto-oncogenes RAS and MYC (let-7 
and miR-98), telomere maintenance (miR-200 family), apoptosis (miR-29 and miR-34 
family), angiogenesis (miR-126) and invasion (miR-200 family) [70]. The overall 
dysregulation of such processes due to microRNA altered expression affects the 
controlled cell growth, the regulation of apoptosis, genetic stability and promotes cell 
invasiveness and formation of new vessels that allow tumour propagation. A link 
between microRNAs and lung cancer metastasis has also been established: miR-148a 
and miR-9-3 genes have been shown to be hypermethylated in lung tumours, which was 
associated to the presence of lymph node metastasis [52]. 
 
miR-126 and miR-126* 
 
miR-126 and miR-126* are intronic microRNAs processed from the same 
precursor pre-microRNA. They locate in intron 7 of the epidermal growth factor-like 
domain 7 (EGFL7) gene. (Fig. 5) [71]. miR-126 has been extensively studied, but little 
information is available on its complement miR-126*. 
EGFL7 is a 30 kDa protein highly expressed in the vascular endothelium 
during embryonic development. Upon birth, its expression decreases dramatically and 
remains restricted mainly to sites of active vascular remodelling and in a small subset of 
vessels in highly vascularized organs, such as the lung, heart and kidney. Although the 
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functions of this protein have not been fully understood yet, EGFL7 is believed to be 
involved in vasculogenesis. In addition, a role in angiogenesis sprouting has also been 
suggested [72]. Interestingly, recent studies support the hypothesis that many of the 
functions previously attributed to EGFL7 based on knock-down/out studies may in fact 
be a reflection of the loss of miR-126 [73]. Kuo and colleagues generated two mouse 
lines, one with an EGFL7 protein deletion and one with a miR-126 deletion. EGFL7-/- 
mice were phenotipically normal and born at the expected frequency, whereas miR-126-
/- mice presented 50% of embryonic lethality and vascular defects that had previously 
been attributed to EGFL7 loss. These defects comprise vascular leakage and 
haemorrhaging, which indicate an important role of miR-126 in angiogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. EGFL7 gene. This gene contains 9 exons that originate the EGFL7 protein. However, its intron 
7 also constitutes an important part of the gene, by originating a pre-microRNA. This pre-microRNA can 
then be processed and form two different microRNAs, miR-126 and miR-126* (adapted from [69]).  
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mir-126 expression is downregulated in several human cancers [74] [75] [76] 
and together with miR-335 it was one the first microRNAs to be described as a 
metastasis-suppressor in breast cancer. In this type of cancer, low miR-126 expression 
correlates with poor metastasis-free survival and its restoration leads to suppression of 
tumour growth and metastasis [50]. In gastric cancer, its expression has been shown to 
be associated to clinicopathological parameters, such as tumour size, lymph node 
metastasis, local invasion and TNM stage [75]. In lung cancer, both mir-126 and mir-
126* have been reported to present low expression [68]. Overexpression of miR-126 in 
tumourigenic cell lines has shown to inhibit cell growth by inducing cell cycle arrest in 
G0/G1 phase, migration, adhesion and invasion, and  it lead to tumour size reduction in 
vivo [75] [77] [78]. Although miR-126* effects have not been so widely approached, its 
overexpression in a prostate cancer cell line was shown to decreased cell migration and 
invasion [79]. These studies also identified some miR-126 and miR-126* targets that 
are involved in various tumourigenic processes, as well as molecules that regulate these 
microRNAs (Fig. 6).  
One of the mechanisms underlying miR-126 downregulation is host gene 
methylation. EGFL7 promoter has been shown to be hypermethylated in bladder and 
prostate tumour and tumour cell lines. When treating these cell lines with 5-Aza-dC, 
miR-126 expression was partially restored [74]. 
The importance of both miR-126 and miR-126* in cancer, namely pulmonary 
carcinoma, is thus quite supported by several studies. Nonetheless, there is still much to 
uncover on this issue. 
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OBJECTIVES 
 
miR-126 and miR-126* downregulation in pulmonary carcinoma has already 
been reported. However, information is lacking regarding many aspects of their role in 
pathology and the mechanisms underlying their dysregulation. 
The main objective of this project was to characterize miR-126 and miR-126* 
expression in patient samples of pulmonary squamous carcinoma and adenocarcinoma. 
We intended to compare their expression in pulmonary parenchyma, primary tumour 
and lymph node metastasis and detect differences according to clinicopathological 
parameters (TNM stage, age, gender and histological type). At the same type, we 
compared the expression of miR-126 and miR-126* in between.  
Figure 6. miR-126 and miR-126 functions and regulation. miR-126 has been associated to several cellular 
processes. So far, targets/modulators related to angiogenesis, cell proliferation, migration and invasion, 
inflammation and cell differentiation have been identified. miR-126* has been less studied, but a link has 
also been established between this microRNA and tumourigenic cell properties. (adapted from [69].) 
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The second objective of this project approached to the mechanism of 
microRNA dysregulation and comprised the study of the methylation pattern of miR-
126 and miR-126* host gene, EGFL7.    
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Matherials and Methods 
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Tissue samples 
 
This study comprised 37 formalin-fixed paraffin-embedded (FFPE) samples of 
bronchial-pulmonary carcinomas, collected from the Archives of the Anatomical 
Pathology of the Service of Pathology of the Hospitais da Universidade de Coimbra, 
surgically-resected between 2005 and 2010. These samples comprised 10 
adenocarcinomas and 9 squamous cell carcinomas without lymph node metastasis, as 
well as 10 adenocarcinomas and 8 squamous cell carcinomas already with hillum and/or 
mediastinal lymph node metastasis. Data was collected regarding clinical and 
pathological information of each patient from the Pathology Registry (Table II).  For 
each sample, at least two tumoural sections were selected after H&E staining, in order 
to gather the appropriate representative tumoural fields that allowed WHO 2004 lung 
cancer tumour classification [54]. Representative pulmonary parenchyma distant from 
each carcinoma and lymph node metastasis (when metastasis were present) were also 
identified by a pathologist. 
 
miR-126 and miR-126* target prediction 
 
Target prediction was made with three softwares: miRanda 
(http://www.microrna.org/), PicTar (http://pictar.mdc-berlin.de/) and TargetScan 5.2 
(http://targetscan.org/). For miR-126* target prediction with TargetScan 5.2, nucleotides 
2-8 were used. This sequence was obtained from miRBase (http://www.mirbase.org/). 
Information obtained from these softwares was then crossed and only targets with 
higher scores and predicted by at least two of the softwares were considered (Table III).  
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 Sample Differentiation/Pattern TNM Gender Age 
(years) 
SCC 
without LNM 
 
 
1 well differentiated pT2 N0 Mx M 84 
2 well differentiated pT1 N0 Mx M 43 
3 well differentiated pT1 N0 Mx M 64 
4 well differentiated pT2 N0 Mx M 65 
5 well differentiated pT2 N0 Mx M 65 
6 well differentiated pT2 N0 Mx M 74 
7 well differentiated pT2 N0 Mx M 58 
8 well differentiated pT3 N0 Mx M 66 
9 well differentiated pT1 N0 Mx F 71 
SCC 
with LNM 
10 well differentiated pT2 N1 Mx M 64 
11 well differentiated pT2 N2 Mx M 48 
12 Poorly differentiated pT1 N1 Mx M 62 
13 well differentiated pT2 N1 Mx M 69 
14 well differentiated pT1 N1 Mx M 65 
15 well differentiated pT2 N1 Mx M 65 
16 well differentiated pT2 N1 Mx M 68 
17 well differentiated pT1 N1 Mx M 72 
Adenocarcinoma 
without lymph 
node metastasis 
18 solid (acinar) pT4 N0 Mx F 60 
19 papillary (BA) pT2 N0 Mx M 71 
20 acinar (BA, papillary) p T2 N0 Mx F 75 
21 papillary (micropapillary, acinar, BA) p T2 N0 Mx M 73 
22 acinar (mucinous BA) p T2 N0 Mx M 48 
23 acinar  pT1 N0 Mx M 75 
24 acinar pT1 N0 Mx F 64 
25 acinar (solid with mucin) pT2 N0 Mx F 49 
26 microacinar (solid) pT2 N0 Mx F 59 
27 acinar (solid) pT1 N0 Mx M 60 
ADC  
with LNM 
28 acinar (micropappilary, BA) pT1 N2 Mx M 63 
29 pappilary pT2 N1 Mx M 59 
30 solid (acinar, micropappilary) pT2 N1 Mx F 77 
31 micropappilary (microglandular) pT2 N2 Mx F 51 
32 acinar (microacinar, solid) pT1 N1 Mx M 61 
33 acinar (microacinar, micropapillary) pT2 N1 Mx F 70 
34 acinar (papillary) pT2 N2 Mx M 68 
35 acinar (BA, micropapillary) pT2 N1 Mx F 77 
36 acinar (BA, papillary) pT2 N1 Mx F 44 
37 papillary pT1 N1 Mx F 62 
ADC 
   without LNM 
SCC – squamous cell carcinoma; LNM – lymph node metastasis; ADC – adenocarcinoma; BA - bronchioloalveolar 
Table II. Tissue samples and clinicopathological data.  
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microRNA Putative target Predicted by 
miRanda PicTar TargetScan 
miR-126 PTPN9 x x x 
KANK2 x  x 
PLXNB2 x  x 
ADAM9 x  x 
PLK2  x x 
CRK  x x 
RGS3  x x 
FBXO33  x x 
SLC7A5  x x 
miR-126* HOXC8 x  x 
ESRRG x  x 
MAP3K2 x  x 
AKNA  x x 
KIAA0355 x  x 
MEF2D  x x 
ARID1A  x x 
FGF7  x x 
GRID1 x  x 
MFAP4 x  x 
HDAC4  x x 
MAT2B  x x 
RFX4 x  x 
HOXA13 x  x 
PPARGC1A  x x 
Table III. miR-126 and miR-126* target prediction. Targets predicted by miRanda, PicTar and 
TargetScan. Putative targets listed were predicted by at least 2 of the softwares.  
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MIR-126 AND MIR-126* EXPRESSION 
 
Laser microdissection 
 
MembraneSlide 1.0 Pen slides with a polyethylene naphtalate membrane (Carl 
Zeiss MicroImaging GmbH, Jena, Germany) were used for laser microdissection. The 
slides, highly absorptive in the UV-A range, were irradiated with UV light for 20 
minutes to make the membrane more hydrophilic and thus promote tissue adherence. 8 
μm-cuts of tissue were made on a Leica 2235 microtome (Leica Microsystems, 
Nussloch, Germany) previously washed with RNase Zap (Sigma Aldrich, St. Louis, 
MO, USA). Cuts were placed on water at 60 ºC and then transferred to membrane 
slides, which were kept on the oven at 30 ºC until they were dry. The slides were stored 
at -20 ºC until they were used for laser microdissection. Prior to laser microdissection, 
sample cuts were deparaffinized by a 2-minute passage in xylene and a 1-minute 
passage in pure ethanol (both reagents from Merck, Darmstadt, Germany).  
Laser microdissection was performed with PALM Laser Microdissection 
System (Carl Zeiss MicroImaging) (Fig. 7), which consists on an inverted optical 
microscope coupled to a video system and to a UV-A laser beam. Images of the tissue 
were visualized on the microscope and the areas of interest were selected using the 
PALM RoboMover and Navigator software. In order to correctly identify the regions of 
interest and prevent the removal of unwanted types of cells, an H&E slide from the 
same sample was visualized during the procedure. Cutting was performed at 200x 
amplification. Tissue fragments were catapulted to the adhesive cap of an eppendorf 
(Adhesive Cap 500 clear, Carl Zeiss MicroImaging). For primary tumours and lymph 
node metastasis, an area of approximately 2,000,000 μm2 was removed, whereas for 
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pulmonary parenchyma this was increased to 4,000,000 μm2, since the tissue had a 
lower cell density. After microdissection, samples were stored at -20 ºC.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Laser microdissection. Laser microdissection of a sample of adenocarcinoma, using PALM 
Laser Microdissection System, 200x magnification.  (A) H&E-stained slide, used to confirm the 
tumourigenic and non-tumourigenic areas in the sample. Polyethylene naphtalate-membrane slide from 
the same sample, after (B) selecting the tumour area and (C) laser ablation and tissue collection.  T – 
tumour cells; F – fibroblasts; L – lymphocytes. 
(A) 
(B)
) 
(C) 
L 
F 
T 
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RNA extraction 
 
RNA extraction from microdissected tissue was performed using miRNeasy 
FFPE Kit (Qiagen, Valencia, CA, USA). The steps of paraffin removal were 
disregarded, since it had been accomplished prior to microdissection. The remaining 
procedure was performed according to the manufacturer’s protocol “Copurification of 
total RNA and miRNA from FFPE tissue sections”. RNA was eluted in 17 μl of RNase-
free water. All the material and equipment used that were not from the kit was washed 
with RNase Zap. 
 
Real-time Polymerase Chain Reaction (Real-time PCR) 
 
Extracted RNA was reverse transcribed to cDNA using miScrip Reverse 
Transcription Kit (Qiagen). 15 μl of template RNA form each sample were used. 
Reversion transcription was performed on a MyCyclerTM thermal cycler (Bio-Rad 
Laboratories, Hercules, CA, USA). cDNA was stored at -20 ºC until real-time PCR was 
performed. Expression of miR-126 and miR-126* was evaluated by real-time PCR 
using miScript SYBR® Green PCR Kit, following the protocol “Real-Time PCR for 
Detection of miRNA or Noncoding RNA” (Qiagen) and using RUB6 snRNA for 
normalization. Primers were purchased from Qiagen and reconstituted with TE , pH 8.0 
(10 mM Tris-Cl pH 8.0; 1 mM EDTA, reagents from Sigma Aldrich, St. Louis, MO, 
USA and Roche Applied Science, Indianapolis, IN, USA respectively). Reactions were 
performed on 96-well plates, using 2 μl of template cDNA. Each set of primers was 
used on a different plate and reactions were performed in duplicate, using two wells 
without DNA as negative controls. Since more than one plate was needed for each 
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microRNA and normalizer, two samples were repeated from one plate to the other, for 
inter-run calibration. After dispensing the reaction mix into the wells, the plates were 
covered with a coverslip and briefly centrifuged. Real-time PCR was then performed on 
LightCycler® 480 II (Roche, Basel, Switzerland) using LightCycler® 480 Software 
release 1.5.0. 40 cycles of amplification were performed. Cq was calculated using the 
Second Derivative Maximum Method. These data were then analyzed using 
qBasePlus® Software (Biogazelle, Ghent, Belgium), performing relative quantification 
according to the formula ΔCq = CqmicroRNA – CqRUB6.  
 
Statistical analysis 
 
Statistical analysis was performed with Graph Pad Prism 5 software. Statistical 
significance of differences in microRNA expression was assessed by: Friedman test 
followed by Dunn’s Multiple or Wilcoxon signed rank test when comparing matched 
tissues and Mann Whitney test when comparing tissues of unpaired samples. p<0.05 
was considered significant. 
 
METHYLATION ANALYSIS OF EGFL7 GENE PROMOTER 
 
Manual microdissection 
 
Manual microdissection was performed on a Leica RM 2135 microtome. Areas 
to be studied were marked on the paraffin block using the corresponding H&E slide for 
identification of the fields and 10 μm cuts were made (5-25 cuts, depending on the size 
40 
 
of the fragment). Distant lung parenchyma, primary tumours and lymph node metastasis 
samples were microdissected to follow the appropriate technical procedures. 
 
DNA extraction 
 
DNA was extracted with QIAamp DNA MiniKit (Qiagen). Prior to extraction, 
samples were deparaffinized following the protocol “Isolation of genomic DNA from 
paraffin-embedded tissue”. However, instead of adding 1200 µl of xylene/ethanol and 
then centrifuge, these steps were divided into two, adding only 600 µl each time. DNA 
extraction was then performed according to the protocol “DNA Purification from 
Tissues” and following the manufacturer’s instructions. The optional centrifugation for 
DNA purification was performed. For the elution step, DNA was incubated with 50 μl 
AE for 5 min before centrifugation. After extraction, DNA samples were quantified and 
their purity determined using GeneQuant pro (Biochrom, Cambridge, UK). Absorbance 
at 260 nm was used to calculate the concentration of DNA in the samples and the ratio 
260/280 was used to evaluate purity. DNA was then stored at -20 ºC until bisulfite 
conversion. 
 
Bisulfite conversion 
 
DNA samples were treated with sodium bisulfite. Bisulfite conversion and 
subsequent DNA recovery was performed using EpiTect Bisulfite Kit (Qiagen), 
according to the Protocol “Sodium Bisulfite Conversion of Unmethylated Cytosines in 
DNA Isolated from FFPE Tissue Samples”. For each reaction, 200 ng of DNA were 
used. At the recovery step, DNA was eluted in 40 μl. 
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Methylation-specific Polymerase Chain Reaction (MS-PCR) 
 
EGFL7 promoter sequence was obtained from Transcriptional Regulatory 
Element Database (http://rulai.cshl.edu/cgi-bin/TRED/). Primers for MS-PCR were then 
designed using 2 softwares, MethPrimer (http://www.urogene.org/methprimer/) (Fig. 8; 
Table IV) and MethylPrimer Express (Applied Biosystems). CpG island prediction 
(GC≥50%) was used for primer design. Primers were designed for the first CpG island. 
Set number 5 was selected for MS-PCR. 
 
 
 
 
Controls for MS-PCR were obtained from Qiagen, consisting in a methylated 
and an unmethylated sequence, both treated with sodium bisulfite (EpiTect Control 
Figure 8. Promoter region of EGFL7. Image obtained on MethPrimer software. This promoter 
presents 2 CpG islands (blue). Five sets of primers were obtained for MS-PCR. 
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DNA, methylated, and EpiTect Control DNA, unmethylated). Primers were obtained 
from TIB Molbiol (Berlin, Germany).  
 
 
 
PCR was performed using a master mix with 3.3x NH4, 2mM or 3mM of Mg
2+ 
(Bioline, London, UK), 16.6% glycerol (Merck), 300 µg/mL cresol red (Sigma Aldrich, 
St. Louis, MO, USA), 600 µM of each nucleotide and 0.4 U/ μl of Taq DNA 
polymerase (Bioline). Concentrations of 50 nM, 300 nM or 900 nM of each primer were 
tested. PCR conditions: initial denaturation for 30 s at 95 ºC, amplification of 65 cycles 
of 10 min at 95 ºC, 30 s at 60 ºC and 30 s at 72 ºC and final extension for 10 minutes at 
72 ºC. An alternative approach comprising a pre-amplification step of 20 cycles 
Set Primer Tm GC% Sequence 
1 Mehylated Forward 
Methylated Reverse 
Unmethylated Forward 
Unmethylated Reverse 
59.53 
59.68 
54.72 
59.00 
36 
52 
24 
36 
GGCGTAGGGGTTTTTAATTTTAATAC 
GCCCACACTAACGAAACTACG 
TGTAGGGGTTTTTAATTTAATATGT 
AAACACCCACACTAACAAAACTACA 
2 Mehylated Forward 
Methylated Reverse 
Unmethylated Forward 
Unmethylated Reverse 
59.53 
59.68 
55.51 
59.00 
36 
52 
27 
36 
GGCGTAGGGGTTTTTAATTTAATAC 
GCCCACACTAACGAAACTACG 
GTGTAGGGGTTTTTAATTTAATATGT 
AAACACCCACACTAACAAAACTACA 
3 Mehylated Forward 
Methylated Reverse 
Unmethylated Forward 
Unmethylated Reverse 
58.16 
59.68 
54.72 
59.00 
36 
52 
24 
36 
CGTAGGGGTTTTTAATTTAATACGT 
GCCCACACTAACGAAACTACG 
TGTAGGGGTTTTTAATTTAATATGT 
AAACACCCACACTAACAAAACTACA 
4 Mehylated Forward 
Methylated Reverse 
Unmethylated Forward 
Unmethylated Reverse 
56.72 
59.68 
54.72 
59.00 
33 
52 
24 
36 
GCGTAGGGGTTTTTAATTTAATAC 
GCCCACACTAACGAAACTACG 
TGTAGGGGTTTTTAATTTAATATGT 
AAACACCCACACTAACAAAACTACA 
5 Mehylated Forward 
Methylated Reverse 
Unmethylated Forward 
Unmethylated Reverse 
59.53 
59.68 
58.32 
59.00 
36 
52 
30 
36 
GGCCTAGGGGTTTTTAATTTAATAC 
GCCCACACTAACGAAACTACG 
GGTGTAGGGGTTTTTAATTTAATATGT 
AAACACCCACACTAACAAAACTACA 
Table IV. Primer design. Sets of primers obtained with MethPrimer software. 
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followed by 45 cycles was also tested, as well as different annealing temperatures (from 
58 ºC to 65 ºC). PCR reactions were performed on a MyCyclerTM thermal cycler or a 
MJ MiniTM Gradient thermal cycler (Bio-Rad Laboratories). PCR products were 
visualized in an ethidium bromide-stained 2% agarose gel with TBE (ethidium bromide 
from Sigma Aldrich, agarose fom Roche Applied Systems and TBE from Bio-Rad 
Laboratories). 
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miR-126 and miR-126* expression in pulmonary squamous cell carcinoma 
 
In order to evaluate the role and diagnostic potential of miR-126 squamous cell 
carcinoma, we determined its relative expression in pulmonary parenchyma and primary 
tumours of samples without lymph node metastasis (Fig. 9A). miR-126 was found to  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. miR-126 expression in squamous cell carcinoma samples. (A) Expression in pulmonary parenchyma  and tumour of 
samples without lymph node metastasis. (B) Expression in pulmonary parenchyma, primary tumour and lymph node metastasis. 
The data on the graphs in the left represent the mean value of duplicate measurements by Real-Time PCR and standard deviation 
(Y axis in logarithmic scale). Expression was normalized using RNUB6. The data of the graphs in the right represent mean ± 
SEM. (** p<0.01 and * p<0.05, for matched samples). PP – pulmonary parenchyma; LNM – lymph node metastasis
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present a lower expression in all tumour samples comparatively to matched pulmonary 
parenchyma, a difference that was highly significant. A similar analysis was performed 
for samples presenting lymph node metastasis and miR-126 expression and this type of 
cells was also evaluated (Fig. 9B). Consistently to what was observed for the samples 
without lymph node metastasis, all primary tumours showed a decreased miR-126 
expression comparatively to pulmonary parenchyma. Lymph node metastasis also had 
lower levels of miR-126 than matched non-tumour tissue across all samples. However, 
the expression of miR-126 in primary tumours and matched lymph node metastasis did 
not present such a clear pattern: whereas for some samples its expression was lower in 
primary tumours, for others the opposite situation was observed. No significant 
differences were found between the two types of tissue. For further evaluation of the 
role of miR-126 in metastatic potential, its expression was compared in primary 
tumours of samples with and without lymph node metastasis (Fig. 10). No significant 
differences were found between these carcinomas (p=0.1139). 
 
 
 
 
 
 
 
 
 
 
Figure 10. miR-126 expression in squamous cell carcinoma with and without lymph node 
metastasis. Bars represent mean ± SEM. w/o LNM – without lymph node metastasis; w/ LNM – with 
lymph node metastasis 
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Similarly to the analysis made for miR-126, the expression of miR-126* was 
also evaluated in the different types of tissue of samples without (Fig. 11A) and with 
lymph node metastasis (Fig. 11B). As observed for its complement, miR-126* 
expression was found to be decreased in all primary tumours comparatively to matched 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
Figure 11. miR-126* expression in squamous cell carcinoma samples. (A) Expression in pulmonary parenchyma and tumour 
of samples without LNM. (B) Expression in pulmonary parenchyma, primary tumour and LNM. The data on the graphs in the 
left represent the mean value of duplicate measurements by Real-Time PCR and standard deviation (Y axis in logarithmic scale). 
Expression was normalized using RNUB6. The data of the graphs in the right represent mean ± SEM. (** p<0.01 and * p<0.05, 
for matched samples). PP – pulmonary parenchyma; LNM – lymph node metastasis  
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pulmonary parenchyma, the same being verified in lymph node metastasis. Also 
resembling what was observed for miR-126, miR-126* had no consistent alterations in 
lymph node metastasis when compared to primary tumours and no significant 
differences were detected between carcinomas with and without lymph node metastasis 
(p=0.0927) (Fig.12). 
 
 
 
 
 
 
 
Expression of miR-126 and miR-126* was also evaluated according to the age 
of the patients (equal or inferior to 70 years/superior to 70 years) but no significant 
differences were found (p=0.8651 for miR-126 and p=0.6919 for miR-126*). Gender 
differences were not analysed due to reduced number of female patients. 
 
 
miR-126 and miR-126* expression in pulmonary adenocarcinoma 
 
The parameters considered in squamous cell carcinoma were also studied in 
adenocarcinoma for both miR-126 and miR-126*. miR-126 expression was lower in all 
Figure 12. miR-126* expression in squamous cell carcinomas with and without lymph node 
metastasis. Bars represent mean ± SEM. w/o LNM – without lymph node metastasis; w/ LNM – 
with lymph node metastasis 
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samples of tumours without lymph node metastasis relatively to pulmonary parenchyma 
(Fig. 13A) and this decrease was highly significant. This was also verified in samples  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. miR-126 expression in adenocarcinoma. (A) Expression in pulmonary parenchyma (normal) and tumour of samples 
without lymph node metastasis. (B) Expression in pulmonary parenchyma (normal), primary tumour and lymph node metastasis 
(LNM). The data on the graphs in the left represent the mean value of duplicate measurements by Real-Time PCR and standard 
deviation (Y axis in logarithmic scale). Expression was normalized using RNUB6. The data of the graphs in the right represent 
mean ± SEM. (** p<0.01 and * p<0.05, for matched samples). PP – pulmonary parenchyma; LNM – lymph node metastasis 
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with lymph node metastasis, although one of them presented higher miR-126 expression 
in the tumour (Fig. 13B). Lymph node metastasis presented a wide variation of miR-126 
expression, as observed for squamous cell carcinoma, and significant differences were 
only found relatively to matched parenchyma (Fig. 13B). Primary tumours from patients 
with and without metastasis also presented no differences in miR-126 expression (Fig. 
14).  The same results were obtained for miR-126* when comparing their expression in 
the different types of tissue (Fig. 15 and Fig. 16).  
 
 
 
 
 
 
 
 
No differences were found according to age (p=0.3641 for miR-126 and 
p=0.4833 for miR-126*). However, when comparing the expression of miR-126 in 
tumours from female and male patients, a more pronounced decrease was found to be 
associated to female gender (Fig. 17). This was not significant for miR-126* when not 
taking the expression in parenchyma in consideration. Nonetheless, the difference was 
almost significant (p=0.0575).  
 
 
Figure 14. miR-126 expression in adenocarcinomas with and without lymph node metastasis. 
Bars represent mean ± SEM. w/o LNM – without lymph node metastasis; w/ LNM – with lymph 
node metastasis 
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Figure 15. miR-126* expression in adenocarcinoma samples. (A) Expression in pulmonary parenchyma and tumour of samples 
without LNM. (B) Expression in pulmonary parenchyma, primary tumour and LNM. The data on the graphs in the left represent 
the mean value of duplicate measurements by Real-Time PCR and standard deviation (Y axis in logarithmic scale). Expression 
was normalized using RNUB6. The data of the graphs in the right represent mean ± SEM. (** p<0.01 and * p<0.05, for matched 
samples). PP – pulmonary parenchyma; LNM – lymph node metastasis 
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Differences in miR-126 and miR-126* expression between squamous cell 
carcinoma and adenocarcinoma 
 
Since adenocarcinomas and squamous cell carcinomas are very different types 
of carcinoma, we compared the expression of miR-126 and miR-126* in the primary 
Figure 16. miR-126* expression in adenocarcinomas with and without lymph node metastasis. Bars 
represent mean ± SEM. w/o LNM – without lymph node metastasis; w/ LNM – with lymph node metastasis 
Figure 17. Adenocarcinomas according to gender. Expression of (A) miR-126 and (B) miR-126* in 
adenocarcinomas from female and male patients. Bars represent mean ± SEM. (* p<0.05) 
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Figure 19. Pulmonary parenchyma according to gender and histological type. (A) Expression of miR-126 and 
(B) miR-126* in pulmonary parenchyma. Bars represent mean ± SEM. (*** p<0.001, ** p<0.01 and * p<0.05) SCC 
– squamous cell carcinoma; ADC – adenocarcinoma. 
 
tumours of these two histological types. This analysis was made only for male gender. 
miR-126 and miR-126* presented lower expression in squamous cell carcinomas than 
in adenocarcinomas (Fig. 18). We then compared the samples of pulmonary 
parenchyma according to three groups: male patients with squamous cell carcinoma, 
male patients with adenocarcinoma and female patients with adenocarcinoma. 
Pulmonary parenchyma of male patients with adenocarcinoma presented a lower 
expression of both miR-126 and miR-126* than the two other groups (Fig. 19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Tumours from male patients according to histological type. (A) Expression of miR-126 and 
(B) miR-126* in tumours. Bars represent mean ± SEM. (* p<0.05) SCC – squamous cell carcinoma; ADC – 
adenocarcinoma. 
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Compared expression of miR-126 and miR-126* 
 
Since miR-126 and miR-126* are processed from the same precursor, we made 
a comparative analysis of their expression considering five types of tissue: pulmonary 
parenchyma, squamous cell carcinoma primary tumour, adenocarcinoma primary 
tumour, lymph node metastasis of squamous cell carcinoma and lymph node metastasis 
of adenocarcinoma (Fig. 20). No significant differences were found in any of these 
tissues.  
 
 
 
 
 
 
 
 
 
 
 
 
 
EGFL7 promoter methylation 
 
PCR was performed using the primers designed with MethPrimer software. 
However, we did not succeed on amplifying the control for the unmethylated sequence 
in any of the conditions tested. 
Figure 20. Compared expression of miR-126 and miR-126*. Expression in pulmonary parenchyma (PP), 
and primary tumour and lymph node metastasis (LNM) of squamous cell carcinoma (SCC) and 
adenocarcinoma (ADC). Comparison was made considering the matched values of miR-126 and miR-126* 
for each case. Bars represent mean ± SEM. 
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Squamous cell carcinoma and adenocarcinoma are the most prevalent types of 
lung cancer (25% and 40%, respectively). Although they have been previously 
categorized in the same broad group of non-small cell lung cancer, this classification is 
nowadays not considered to be significant or useful, since the carcinomas of this group 
present several differences both at the molecular and histological levels and regarding 
therapy [54]. Realizing that squamous cell carcinomas and adenocarcinomas are so 
different brings the need of a more deep and detailed characterization in order to 
elucidate the mechanism underlying their development and the potential clinical 
implications of such studies. 
microRNAs are a broad family of small regulatory RNA molecules that act at 
the post-transcriptional level and whose importance in carcinogenesis has been recently 
discovered.  In the last years they have been a major focus of cancer research and their 
central role in carcinogenesis is now widely recognized. microRNA alterations in cancer 
and the molecular consequences have been approached for several types of cancer and 
tumours at different stages of progression [9] [46] [80]. Lung cancer is no exception and 
in fact it was one of the first types of cancer for which cancer-related microRNAs have 
been identified [44]. Several microRNAs present altered expression in lung cancer, 
directly altering the levels of a wide range of targets. microRNA profiles have been 
proven to be very useful in lung cancer diagnosis and prognosis, as well as to 
distinguish different histological types of cancer [70]. 
miR-126 and miR-126* are two microRNAs that share a common precursor 
and that have been implicated in lung cancer, with reports of decreased expression in 
NSCLC [68] [76].  In addition, miR-126 is underexpressed in highly metastatic breast 
cancer cell lines and its expression has been shown to be lower in the breast tumours of 
patients that suffered metastatic relapse than in those who did not [50]. However, their 
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differential expression in adenocarcinoma and squamous cell carcinoma lung cancer has 
not been reported. Likewise, information is lacking regarding a role of these 
microRNAs on metastatic potential of lung carcinomas.   
A striking characteristic of microRNAs is that total complementarity to the 
target mRNA is not usually required for silencing to occur. As a result, most 
microRNAs are predicted to have several targets [38]. This potential to regulate such a 
wide range of mRNAs makes microRNAs central players in the main cellular processes 
[39]. However, knowledge on the precise rules that define a mRNA as a microRNA 
target is still lacking. Consequently, the bioinformatic tools used are still not refined 
enough as to accurately identify the targets of microRNAs. Although these tools are 
widely used for target prediction, they often present false positives and thus this 
information must be experimentally validated [81]. Nonetheless, despite their 
inaccuracies, bioinformatic approaches have been deeply valuable for predicting the 
role of microRNAs in cellular regulation. In order to determine whether miR-126 and 
miR-126* are potential tumour- and metastasis-suppressors in lung cancer, their 
putative targets were determined using bioinformatic approaches. 3 softwares were used 
for target prediction: miRanda, PicTar and TargetScan, according to Elton and 
colleagues [81]. These algorithms are based in different characteristics of microRNAs 
and targets and therefore predict different binding sites [82]. Three of the predicted 
targets, protein tyrosine phosphatase, non-receptor type 9 (PTPN9), v-crk sarcoma virus 
CT10 oncogene homolog (CRK) and solute carrier family 7 member 5 (SCL7A5) have 
already been confirmed to be direct targets of miR-126 [76] [83] [84]. Polo-like kinase 
2 (PLK2) has not been experimentally validated, but its expression inversely correlates 
to miR-126 expression [85]. Several of the predicted targets are known to be involved in 
cancer development and progression, such as regulator of G-protein signaling 3 (RGS3), 
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PLK2 and histone deacetylase 4 (HDAC4) [86] [87] [88]. Plus, some of them have been 
specifically implicated in lung carcinoma. For instance, ADAM metallopeptidase 
domain 9 (ADAM9) expression has been found to correlate with NSCLC metastasis to 
the brain [89] and HOXC8 is involved in lung cancer progression [90]. In addition, both 
ADAM9 and homeobox C8 (HOXC8) have been shown to alter the expression of 
angiogenic factors [91] [92]. However, it should be noted that some of the miR-126 
targets in this list also present miR-126* binding sites: PTPN9, KN motif and ankyrin 
domains 2 (KANK2), ADAM9, PLK2, F-box protein 33 (FBXO33) have at least one of 
these sites, although they present lower scores (predicted by miRanda). It is important to 
keep in mind that putative targets predicted by only one program and presenting low 
scores have been experimentally confirmed. Such is the case of solute carrier family 45 
member 3 (SLC45A3), for instance, which has been proven to be directly targeted by 
miR-126* [79]. Thus, it is possible that these can be regulated by both miR and miR* 
strands. Likewise, it is highly probable that these microRNAs target many other 
molecules not not predicted with the parameters we considered (for example, 
phosphoinositide-3-kinase, regulatory subunit, polypeptide 2 p85 beta (PIK3R2), 
vascular endothelial growth factor A (VEGF-A) and insulin receptor substrate 1 (IRS-1) 
are validated targets of miR-126) [77] [93] [94].   
Taking into account the predicted targets of miR-126 and miR-126* and the 
reported evidence of their role in angiogenesis and in breast cancer metastasis, we 
considered that these microRNAs could be potential metastasis-suppressors in 
pulmonary squamous cell carcinoma and adenocarcinoma. In these carcinomas, lymph 
node metastasis correlate with survival and are therefore an important prognostic factor 
[95]. We therefore intended to compare miR-126 and miR-126* expression in (1) 
pulmonary parenchyma, primary tumour and lymph node metastasis, for both squamous 
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cell carcinoma and adenocarcinoma, (2) tumours with and without lymph node 
metastasis, (3) tumours of patients with squamous cell carcinoma and with 
adenocarcinoma. The elucidation of these parameters could not only contribute for 
understanding the molecular mechanisms underlying lung cancer progression but also 
be important for diagnosis and prognosis. By determining differences in miR-126/miR-
126* expression in primary tumours and lymph node metastasis, it would be possible to 
unravel potential layers of gene expression regulation that are altered in these cells and 
that would help explain the features of the tumour. Comparing their expression in 
adenocarcinoma and squamous cell carcinoma could also determine their potential as 
biomarkers.  
Tumours are now recognized as highly heterogeneous entities, whose 
development and progression is strongly influenced by the respective supporting 
stroma. The tumour microenvironment comprises a broad variety of components in the 
extracellular matrix such as fibroblasts, immune and inflammatory cells and blood-
vessel cells [96]. When characterising a tumour, it is thus important to keep in mind its 
different components and the interactions they establish. Most studies of microRNA 
expression in tumours, namely those regarding miR-126 and miR-126*, evaluate 
expression using the bulk tumoural tissue, without taking in consideration the kind of 
cells that are collected (whether they are tumoural or stromal cells). In this study, we 
intended to characterize the expression of these microRNAs exclusively in neoplastic 
cells. Laser microdissection uses an UV-A laser focused through the microscope to 
promote ablation of cells and tissue by photofragmentation and represents a reliable and 
accurate way to collect specific types of cells since it allows the visualization of the 
tissue under the microscope while selecting the areas to be removed. Therefore, this 
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technique was used to obtain the cells from pulmonary parenchyma, primary tumours 
and lymph node metastasis.  
Due to their small size, evaluating microRNA expression can be a challenging 
task and it is important to choose the best technique for each case. Many studies 
perform microarrays analysis, which allows the study of several microRNAs at once. 
However, this should be only used to obtain a general view of dysregulated 
microRNAs. More quantitative methods should be employed to confirm the levels of 
specific microRNAs [97]. We therefore evaluated the expression of miR-126 and miR-
126* by real-time PCR using SYBR Green detection. SYBR Green is a double-stranded 
DNA-binding agent that fluoresces when bound to DNA. Quantification of the samples 
can thus be made by measuring fluorescence after each extension step. U6 snRNA 
(RNUB6, 45 nt) was used as an endogenous control and normalizing. This snRNA is 
widely used due to its small size, namely in studies on microRNA expression in lung 
cancer [68] [69].  
 
miR-126 and miR-126* expression in pulmonary squamous cell carcinoma 
 
To evaluate the correlation between miR-126 and miR-126* and the 
tumourigenic and metastatic potential of squamous cell carcinoma, we compared the 
microRNA expression in cells from pulmonary parenchyma, primary tumour and lymph 
node metastasis. The decrease found for miR-126 and miR-126* expression between 
parenchyma and tumour is in accordance to what had been previously described [68] 
[76]. However, no differences were found either between primary tumours and 
matching lymph node metastasis or between primary tumours of samples with and 
without lymph node metastasis. These results support previous evidence that miR-126 
and miR-126* play a role in tumourigenesis but suggest that they are particularly 
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relevant in the tumourigenesis of primary lung tumour and not in the spread and 
colonization of other organs. This differs from what has been described for breast 
cancer [50], which could be explained by the fact that microRNAs can play different 
roles in different tumours. A possible explanation for that comes from the work of 
Marks and colleagues, showing that the activity of a microRNA depends on the 
abundance of its target [98]. Consequently, different environments could lead an mRNA 
to be a target in a certain type of tumour and not a target in other type.  
 
miR-126 and miR-126* expression in pulmonary adenocarcinoma 
 
The results obtained for miR-126 and miR-126* expression in adenocarcinoma 
in pulmonary parenchyma, primary tumours and lymph node metastasis resemble those 
verified for squamous cell carcinoma. Therefore, it seems that these microRNAs are 
also involved in tumourigenesis in this type of carcinoma but have not a prominent role 
in metastatic potential. miR-126 and miR-126* expression was also found to be 
different according to gender, a distinction that was not possible to evaluate for 
squamous cell carcinoma due to lack of a representative number of samples from both 
genders. Both microRNAs presented a more decresed expression in the female gender. 
A deeper knowledge on the molecular mechanism of miR-126 and miR-126 activity 
could help understand this difference. Similar patterns have been observed for estrogen 
receptors, for example, which have been proposed to be one of the causes of the 
differences of adenocarcinoma between genders [99]. It should be noticed that although 
no differences were found between miR-126 and miR-126* expression, only miR-126* 
expression was not significantly different in male and female patients when tumour 
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expression was compared. However, the p-value associated to this difference was close 
to a significant value.  
 
Differences in miR-126 and miR-126* expression between squamous cell 
carcinoma and adenocarcinoma 
 
After detecting the decrease of miR-126 and miR-126* in both types of 
carcinoma, a comparison was made between squamous cell carcinoma and 
adenocarcinoma. Since a difference between tumours from female and male patients 
had been previously detected, we performed this analysis according to gender. Only 
tumours from male patients were analysed, due to the lack of samples of squamous cell 
carcinomas from female patients. The differences found between squamous cell 
carcinomas and adenocarcinomas show that these microRNAs are not equally expressed 
in these types of tumour and could therefore be partly responsible for the different traits 
they present.  
A decreased expression of miR-126 and miR-126* was also found in 
pulmonary parenchyma from males with adenocarcinoma comparatively to males with 
squamous cell carcinoma and females with adenocarcinoma. This becomes particularly 
relevant considering that adenocarcinoma of female patients present a lower expression 
of these microRNAs.  Two conclusions come out from these results. First, taking into 
account that adenocarcinomas from female patients presented lower expression of miR-
126/miR-126* than those from male patients, these microRNAs seem to be important 
players of carcinogenesis mainly in women. Another very important conclusion regards 
the use of pulmonary parenchyma as non-tumoural tissue with which tumour tissue is 
compared. Squamous cell carcinomas usually develop in the bronchial epithelium after 
epidermoid metaplasia, but adenocarcinomas develop mainly in the terminal respiratory 
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unit (TRU) and it is thus possible that pulmonary parenchyma that appears 
histologically normal already presents molecular changes that predispose to 
carcinogenesis. In fact, our results support that hypothesis, since pulmonary 
parenchyma from patients with squamous cell carcinomas presented higher expression 
of both miR-126 and miR-126*. Therefore, miR-126 and miR-126* loss correlates with 
the development of a predisposing field to adenocarcinoma.  
Most studies of miR-126 overexpression in lung cancer cell lines have used 
adenocarcinoma cells [77] [78] and described a decrease in cell proliferation. 
Interestingly, a study on which a squamous carcinoma cell line was used, reported that 
miR-126 had no effect on cell proliferation [76]. However, these results are usually 
discussed considering miR-126 effects on lung cancer, without making any distinction 
between squamous cell carcinoma and adenocarcinoma. Considering the results we 
obtained, it becomes clear the importance of taking this distinction into account. 
Similarly, studies validating miR-126 targets should be carried on in these two cell lines 
and not be extrapolated for both histological types.  
 
Compared expression of miR-126 and miR-126*  
 
During processing, microRNAs acquire a duplex structure due to partial self-
complementarity. When associating to RISC, this duplex is unwound and one of the 
strands is selected for target silencing. However, the principles underlying such 
selection remain elusive. Usually, only one of the strands is used in this process and the 
other, named miR*, is degraded. Nevertheless, it has become clear that in many cases 
the other strand can also be used in silencing, although usually on a less extent. This 
process is differentially regulated across tissues [25]. 
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Although both microRNAs have been studied in lung cancer, most studies 
approach miR-126 and no extensive studied has been carried comparing the expression 
of the two microRNAs. We therefore compared the expression of miR-126 and miR-
126* in pulmonary parenchyma and in primary tumours and lymph node metastasis 
from each type of carcinoma. The results obtained suggest that miR-126 and miR-126* 
are equally express in the lung. Therefore this miR* might also be an important factor 
on gene regulation in this tissue, as already verified for prostate cancer [79]. The fact 
that the two microRNAs are underexpressed in cancer and present similar patterns of 
expression suggests that an event anterior to RISC assembly could be one of the causes 
for their downregulation. One of such mechanisms could be methylation of the host 
gene, EGFL7.    
These results have important implications when considering the targets 
silenced through pre-miR-126 expression. So far, most studies on the targets of miR-
126 used a vector with a precursor form that can originate both microRNAs, miR and 
miR*, in a biologically active form. It is thus possible that some of the mRNAs 
identified as miR-126 targets are in fact regulated by miR-126*. Plus, the effects seen 
when overexpressing the these vectors on tumourigenic cell lines could be partly due to 
miR-126*. It is therefore important that miR-expressing vectors that originate only one 
active strand be used when trying to determine specific targets of miR-126 (or miR-
126*), instead of vectors expressing the precursor form of the microRNA. 
 
EGFL7 promoter methylation 
 
Hypermethylation of tumour suppressor genes has been proved to be an 
important event in cancer. This process occurs mainly in the promoters of those genes, 
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in CpG-enriched regions. The importance of methylation in this carcinogenesis is clear 
in studies where the use of demethylating drugs leads to partial restoration of expression 
of genes that are silenced in cancer cells [8]. In lung carcinoma, the methylation of 
some promoters is associated with prognosis [100]. Several studies have approached 
microRNA genes methylation and uncovered some expression patterns that could be 
useful as biomarkers [101]. 
We therefore intended to characterize adenocarcinoma and squamous cell 
carcinoma according to miR-126/miR-126* host gene promoter methylation. These 
microRNAs are processed from the same precursor and thus have the same host gene, 
EGFL7. Esteller and colleagues have shown that it presents in several normal tissues, 
such as colon and skin [52]. Its methylation status in lung, however, was not studied. 
Given the acknowledged importance of miR-126 downregulation in lung cancer, it is 
thus possible that its host gene presents hypermethylation in lung tumour cells. We 
decided to perform methylation analysis with MS-PCR. This technique is based on 
sodium bisulfite treatment followed by PCR using 2 sets of primers, one for the 
methylated sequence and one for the unmethylated sequence. At high temperatures and 
low pH, sodium bisulfite converts unmethylated cytosines to uracil, leaving methylated 
residues unmodified. Consequently, after treating a DNA sample with bisulfite, two 
main sequences can result, according to the methylation pattern. PCR is then performed, 
using primers for the same region, but one designed for the original sequence and other 
designed for the sequence with uracil replacing cytosine.   
Since the second CpG island would be very difficult to amplify, especially 
from paraffined samples, due to its size, we designed primers for the first region. Two 
sets of primers were designed, with 2 softwares. However, the sequences obtained 
presented low levels of GC content and some poly(T) (especially the primers for the 
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unmethylated sequence) which makes the PCR reaction more difficult to perform. In 
fact, when PCR was performed for both methylated and unmethylated controls, no 
amplification was obtained for the unmethylated sequence. This inefficiency was 
verified even when changing several PCR parameters, such as annealing temperature, 
Mg2+ and primer concentration and addition of a pre-amplification step. Therefore, we 
could not proceed with the methylation analysis of the DNA already extracted and 
bisulfite-converted from microdissected samples. Recently, the occurrence of EGLF7 
methylation in primary tumours of NSCLC has been reported, although in a small 
percentage of cases [102]. This study was performed with bisulfite sequencing, thus 
avoiding the issue of designing MS-PCR primers for the CpG region. In fact, the 
authors also attempted to perform MS-PCR and report its inefficiency due to problems 
on primer design. We can therefore conclude that for methylation studies of miR-
126/miR-126* host gene MS-PCR is not a suitable technique and others should be 
considered.  
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Closing Remarks 
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Conclusions 
 
In this study, miR-126 and miR-126* were found to be downregulated in both 
pulmonary squamous cell carcinoma and adenocarcinoma, pointing to a role in 
tumourigenesis, in accordance to what has already been described. However, they do 
not seem to be involved in metastatic potential of these carcinomas, contrary to what 
has been found for miR-126 in breast cancer. miR-126 and miR-126* presented a more 
marked decrease in squamous cell carcinoma, which leads to the hypothesis that they 
could be partly responsible for the differences between the two histological types and 
therefore be useful biomarkers. In adenocarcinoma, both microRNAs presented lower 
expression in female than in male patients. Pulmonary parenchyma from patients with 
adenocarcinoma presented less expression than from patients with squamous cell 
carcinoma, suggesting that miR-126 and miR-126* are important in the early steps of 
adenocarcinoma carcinogenesis. Regardless of the type of tissue (pulmonary 
parenchyma, squamous cell carcinoma or adenocarcinoma), miR-126 and miR-126* 
presented similar expression, which suggests that their downregulation occurs at a 
precursor level and indicates that miR-126* might also play an important role in 
tumorigenesis. A possible mechanism of downregulation could be methylation of the 
host gene promoter. However, MS-PCR is not a feasible technique for this particular 
case, due to difficulties on effective primer design. 
 
Future Perspectives 
 
Most samples used in this study were of stage I or II of TNM stage. Since miR-
126 has been described to have different expression according to TNM stage in gastric 
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cancer, it would be important to perform a similar study for squamous carcinoma and 
adenocarcinoma of the lung.  
Due to the constraints in evaluating the methylation of EGFL7 using MS-PCR, 
other techniques should be considered to proceed with this study. A good alternative 
would be combined bisulfite restriction analysis (COBRA): first, DNA is treated with 
sodium bisulfite and amplified; restriction enzymes that cleave DNA in bisulfite-
sensitive sites are then used. According to the methylation pattern, different fragments 
are then obtained and can be visualized in a gel. This technique has already been proven 
to be suitable for EGFL7 promoter methylation analysis. Therefore, it would allow to 
evaluate the methylation status in our patient cohort and relate it to the differences we 
found in miR-126/miR-126* expression according to type of tissue and tumour 
histological type. 
Having confirmed that both miR-126 and miR-126* are downregulated in 
squamous cell carcinoma and adenocarcinoma, analysing the effects of their 
overexpression in cell lines would allow a better understanding of their role in these 
pathologies. It is important to notice that this should carried on in at least two cell lines, 
one from each of the histological types. In addition, vectors should express the mature 
form of only one of the microRNAs (miR-126 and miR-126*), since a vector expressing 
both forms would make it more difficult to determine whether the observed effects are 
due to miR-126 or miR-126* expression or even a combination of both. After 
overexpression, cell proliferation, migration and invasion should be measured to assess 
the effect of these microRNAs in tumourigenic traits.  
After studying the effects of the microRNAs in tumourigenic cell lines, it 
would be interesting to determine some of their targets. In order to do that, a microRNA 
mimic should be introduced in an adenocarcinoma/squamous carcinoma cell line and 
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the levels of the putative target should be determined by western blot. A decrease in the 
levels of the protein would be evidence that the microRNA has effects on its expression, 
but it would not give information on whether it is a direct or indirect target. That could 
be determined by using a reporter gene containing the 3’ UTR of the putative target, 
since this is usually the region to which microRNAs bind and one of the parameters 
considered in bioinformatic predictions. After transfecting a vector with this gene and 
with the microRNA mimic, a decrease in the levels of the protein of the target would 
mean that microRNA would be directly exerting its effects. Additional information on 
that silencing could be obtained by performing real-time PCR to evaluate the levels of 
the target mRNA. A decrease in mRNA levels would mean that the microRNA would 
be regulating its expression by promoting its degradation, whereas unaltered levels of 
mRNA would be consistent with translation prevention.  
In this study, laser microdissection was performed in order to specifically 
collect tumour cells, avoiding cells of the stroma. Given the recognized importance of 
tumour microenvironment in carcinogenesis, using this procedure to evaluate miR-126 
and miR-126* levels in stroma and compare them to tumour cells could provide a more 
detailed characterization of carcinogenesis of these tumours.  
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